OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-08-18
Last Posted Date
2013-12-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
330
Registration Number
NCT00365859
Locations
🇺🇸

Institute For Behavioral Medicine, Smyrna, Georgia, United States

🇺🇸

Regions Hospital, St. Paul, Minnesota, United States

🇺🇸

Harmonex Neuroscience, Dothan, Alabama, United States

and more 52 locations

Aripiprazole and Lexapro Drug Interaction Study

Phase 1
Completed
Conditions
First Posted Date
2006-08-09
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
25
Registration Number
NCT00361790
Locations
🇺🇸

Local Institution, Lenexa, Kansas, United States

Aripiprazole and Effexor XR Drug Interaction Study

Phase 1
Completed
Conditions
First Posted Date
2006-08-09
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
38
Registration Number
NCT00362271
Locations
🇺🇸

Local Institution, Miami, Florida, United States

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2006-06-20
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00338273
Locations
🇮🇳

Local Institution, Vishakhapatnam, India

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

First Posted Date
2006-06-16
Last Posted Date
2013-12-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
218
Registration Number
NCT00337571
Locations
🇺🇸

Cambridge Health Alliance, Medford, Massachusetts, United States

🇺🇸

Clinical Innovations, Inc., Huntington Beach, California, United States

🇺🇸

University Of Florida, Gainesville, Florida, United States

and more 28 locations

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-06-01
Last Posted Date
2013-12-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
98
Registration Number
NCT00332241
Locations
🇺🇸

Univ Of Nc, Chapel Hill, North Carolina, United States

🇺🇸

Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States

🇺🇸

Marsella, Gregory, Boca Raton, Florida, United States

and more 6 locations

Effect on Cognitive Function of a Treatment With Aripiprazole

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-05-25
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
500
Registration Number
NCT00329810

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

First Posted Date
2006-05-15
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
323
Registration Number
NCT00325689
Locations
🇺🇸

Atp Clinical Research, Inc., Costa Mesa, California, United States

🇺🇸

J. Gary Booker, Md, Shreveport, Louisiana, United States

🇺🇸

Sheppard Pratt Health System, Baltimore, Maryland, United States

and more 44 locations

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-05-03
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
20
Registration Number
NCT00321516
Locations
🇺🇸

Local Institution, Desota, Texas, United States

A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-03-10
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
200
Registration Number
NCT00300846
Locations
🇬🇧

Local Institution, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath